1887

Chapter 65 : Viral Hepatitis

Authors: Hubert G. M. Niesters1, Annelies Riezebos-Brilman2, Coretta C. Van Leer-Buter3
VIEW AFFILIATIONS HIDE AFFILIATIONS
Affiliations: 1: University Medical Centre Groningen, Department of Medical Microbiology, Division of Clinical Virology, Hanzeplein 1, Groningen, The Netherlands; 2: University Medical Centre Groningen, Department of Medical Microbiology, Division of Clinical Virology, Hanzeplein 1, Groningen, The Netherlands; 3: University Medical Centre Groningen, Department of Medical Microbiology, Division of Clinical Virology, Hanzeplein 1, Groningen, The Netherlands
Content Type: Reference
Publication Year: 2016

Category: Immunology

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Preview Magnify
Zoom in
Zoomout

Viral Hepatitis, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH65-1.gif /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH65-2.gif

Abstract:

The term “hepatitis” refers to the inflammation of the liver, and in this chapter the five so-called major or primary viruses that cause this inflammation are described. These are the viruses hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis delta virus (HDV), and hepatitis E virus (HEV). In Table 1, the characteristics of these hepatitis viruses are described. Although there are also secondary viruses that can infect the liver and cause hepatitis, such as cytomegalovirus, Epstein-Barr virus, herpes simplex virus 1, and enterovirus, the five primary viruses account for at least 95% of hepatitis virus infections. They primarily cause an infection of the liver and may infect other organs, while the secondary viruses infect the liver only during the course of a systemic infection.

Citation: Niesters H, Riezebos-Brilman A, Van Leer-Buter C. 2016. Viral Hepatitis, p 620-638. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch65
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Viral Hepatitis
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555818722.ch65-1,webId=/content/author/10.1128/9781555818722.ch65-1,properties={foaf_givenname=Hubert G. M., foaf_name=Hubert G. M. Niesters, foaf_surname=Niesters, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555818722.ch65-aff1]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555818722.ch65-2,webId=/content/author/10.1128/9781555818722.ch65-2,properties={foaf_givenname=Annelies, foaf_name=Annelies Riezebos-Brilman, foaf_surname=Riezebos-Brilman, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555818722.ch65-aff2]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555818722.ch65-3,webId=/content/author/10.1128/9781555818722.ch65-3,properties={foaf_givenname=Coretta C., foaf_name=Coretta C. Van Leer-Buter, foaf_surname=Van Leer-Buter, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555818722.ch65-aff3]]}]]
Citation: Niesters H, Riezebos-Brilman A, Van Leer-Buter C. 2016. Viral Hepatitis, p 620-638. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch65
/content/10.1128/9781555818722.ch65.ch65fig1
FIGURE 1

Typical course of the virological and immunological manifestations of HAV (top) and HEV (bottom). Neither of these viruses results in a chronic infection in the immunocompetent host. Infections with both viruses are in most cases asymptomatic. The virological parameters for both viruses are very similar. Both viruses are transmitted through the fecal-oral route.

10.1128/9781555818722/8722ch65fig1_thmb.gif
10.1128/9781555818722/8722ch65fig1.gif
Image of FIGURE 1
FIGURE 1

Typical course of the virological and immunological manifestations of HAV (top) and HEV (bottom). Neither of these viruses results in a chronic infection in the immunocompetent host. Infections with both viruses are in most cases asymptomatic. The virological parameters for both viruses are very similar. Both viruses are transmitted through the fecal-oral route.

Citation: Niesters H, Riezebos-Brilman A, Van Leer-Buter C. 2016. Viral Hepatitis, p 620-638. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch65
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555818722.ch65.ch65fig2
FIGURE 2

Virological profiles observed in patients infected with HBV. (A) Typical profiles in individuals with an acute HBV infection and subsequent resolution of the infection. HBV DNA is detected during a limited period of time and is ultimately undetectable using molecular techniques. Similarly, HBsAg is not detected anymore. The resolution of the infection and symptoms results in the presence anti-HBsAg antibodies, which is a marker for protection. (B) Profiles observed in individuals with a chronic HBV infection. In these cases, HBsAg and anti-HBc remain positive, while the patterns of HBeAg and anti-HBeAg may vary in time. The latter might be absent in the case of a precore mutation. HBV DNA is detectable at high levels during the whole period of the chronic infection.

10.1128/9781555818722/8722ch65fig2_thmb.gif
10.1128/9781555818722/8722ch65fig2.gif
Image of FIGURE 2
FIGURE 2

Virological profiles observed in patients infected with HBV. (A) Typical profiles in individuals with an acute HBV infection and subsequent resolution of the infection. HBV DNA is detected during a limited period of time and is ultimately undetectable using molecular techniques. Similarly, HBsAg is not detected anymore. The resolution of the infection and symptoms results in the presence anti-HBsAg antibodies, which is a marker for protection. (B) Profiles observed in individuals with a chronic HBV infection. In these cases, HBsAg and anti-HBc remain positive, while the patterns of HBeAg and anti-HBeAg may vary in time. The latter might be absent in the case of a precore mutation. HBV DNA is detectable at high levels during the whole period of the chronic infection.

Citation: Niesters H, Riezebos-Brilman A, Van Leer-Buter C. 2016. Viral Hepatitis, p 620-638. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch65
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555818722.ch65.ch65fig3
FIGURE 3

Virological profiles observed in patients infected with HCV: the course of an HCV infection and the immunological events that follow. Most patients become chronically infected, while a limited number are able to resolve the infection spontaneously. Many patients, whether acutely or chronically infected, do not know that they are infected or are having overt signals of the disease. They do, however, follow these patterns and those who are chronically infected will have clinical symptoms later in life.

10.1128/9781555818722/8722ch65fig3_thmb.gif
10.1128/9781555818722/8722ch65fig3.gif
Image of FIGURE 3
FIGURE 3

Virological profiles observed in patients infected with HCV: the course of an HCV infection and the immunological events that follow. Most patients become chronically infected, while a limited number are able to resolve the infection spontaneously. Many patients, whether acutely or chronically infected, do not know that they are infected or are having overt signals of the disease. They do, however, follow these patterns and those who are chronically infected will have clinical symptoms later in life.

Citation: Niesters H, Riezebos-Brilman A, Van Leer-Buter C. 2016. Viral Hepatitis, p 620-638. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch65
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555818722.ch65.ch65fig4
FIGURE 4

Virological profiles observed in patients infected with HDV. There are two routes of HDV infections. (Top) In the first one, HBV and HDV coinfect the same individual at the same time. Since the individual has not been infected previously with HBV, the replication of HBV and the production of HBsAg control the replication of HDV. As soon as the level of HBsAg is reduced due to the presence of anti-HBsAg, the replication of both HBV and HDV is dramatically reduced, and eventually both HBV DNA and HDV RNA are no longer detected in serum or plasma. Anti-HDV antibodies are present. (Bottom) In the case of a superinfection, HDV replication is enhanced from the beginning since an abundant amount of HBsAg is present in the liver. HDV RNA is detected by real-time amplification technologies as long as HBV replication and thus the production of HBsAg continue. In the case of this chronic infection with HDV, anti-HDV is also detected.

10.1128/9781555818722/8722ch65fig4_thmb.gif
10.1128/9781555818722/8722ch65fig4.gif
Image of FIGURE 4
FIGURE 4

Virological profiles observed in patients infected with HDV. There are two routes of HDV infections. (Top) In the first one, HBV and HDV coinfect the same individual at the same time. Since the individual has not been infected previously with HBV, the replication of HBV and the production of HBsAg control the replication of HDV. As soon as the level of HBsAg is reduced due to the presence of anti-HBsAg, the replication of both HBV and HDV is dramatically reduced, and eventually both HBV DNA and HDV RNA are no longer detected in serum or plasma. Anti-HDV antibodies are present. (Bottom) In the case of a superinfection, HDV replication is enhanced from the beginning since an abundant amount of HBsAg is present in the liver. HDV RNA is detected by real-time amplification technologies as long as HBV replication and thus the production of HBsAg continue. In the case of this chronic infection with HDV, anti-HDV is also detected.

Citation: Niesters H, Riezebos-Brilman A, Van Leer-Buter C. 2016. Viral Hepatitis, p 620-638. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch65
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555818722.ch65
1. Chi H, Haagsma EB, Riezebos-Brilman A, van den Berg AP, Metselaar HJ, de Knegt RJ . 2014. Hepatitis A related acute liver failure by consumption of contaminated food. J Clin Virol 61 : 456– 458.[CrossRef].[PubMed]
2. Stene-Johansen K, Tjon G, Schreier E, Bremer V, Bruisten S, Ngui SL, King M, Pinto RM, Aragonès L, Mazick A, Corbet S, Sundqvist L, Blystad H, Norder H, Skaug K . 2007. Molecular epidemiological studies show that hepatitis A virus is endemic among active homosexual men in Europe. J Med Virol 79 : 356– 365.[CrossRef].[PubMed]
3. Tjon GM, Götz H, Koek AG, de Zwart O, Mertens PL, Coutinho RA, Bruisten SM . 2005. An outbreak of hepatitis A among homeless drug users in Rotterdam, The Netherlands. J Med Virol 77 : 360– 366.[CrossRef].[PubMed]
4. Bower WA, Nainan OV, Han X, Margolis HS . 2000. Duration of viremia in hepatitis A virus infection. J Infect Dis 182 : 12– 17.[CrossRef].[PubMed]
5. Fryer JF, Heath AB, Morris CL Collaborative Study Group . 2013. Collaborative Study to Evaluate the Proposed 2nd WHO International Standard for Hepatitis A Virus (HAV) for Nucleic Acid Amplification Technology (NAT)-Based Assays. WHO ECBS report WHO/BS/2013.2225. World Health Organization, Geneva, Switzerland. http://www.who.int/biologicals/expert_committee/BS_2225_2nd_HAV_IS.pdf.
6. Henriques I, Monteiro F, Meireles E, Cruz A, Tavares G, Ferreira M, Araújo F . 2005. Prevalence of Parvovirus B19 and Hepatitis A virus in Portuguese blood donors. Transfus Apher Sci 33 : 305– 309.[CrossRef].[PubMed]
7. Müller MM, Fraile MI, Hourfar MK, Peris LB, Sireis W, Rubin MG, López EM, Rodriguez GT, Seifried E, Saldanha J, Schmidt M . 2013. Evaluation of two, commercial, multi-dye, nucleic acid amplification technology tests, for HBV/HCV/HIV-1/HIV-2 and B19V/HAV, for screening blood and plasma for further manufacture. Vox Sang 104 : 19– 29.[CrossRef]
8. Heitmann A, Laue T, Schottstedt V, Dotzauer A, Pichl L . 2005. Occurrence of hepatitis A virus genotype III in Germany requires the adaptation of commercially available diagnostic test systems. Transfusion 45 : 1097– 1105.[CrossRef].[PubMed]
9. Quality Control for Molecular Diagnostics . EQA programmes. Quality Control for Molecular Diagnostics, Glasgow, United Kingdom. http://www.qcmd.org/index.php?pageId=3&pageVersion=EN.
10. Ly KN, Klevens RM . 2015. Trends in disease and complications of hepatitis A virus infection in the United States, 1999-2011: a new concern for adults. J Infect Dis 212 : 176– 182.[CrossRef].[PubMed]
11. Dane DS, Cameron CH, Briggs M . 1970. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1 : 695– 698.[PubMed].[CrossRef]
12. Almeida JD, Waterson AP . 1970. [The Australia antigen and its relation to hepatitis]. Internist (Berl) 11 : 73– 77. (In German.)[PubMed]
13. Martin P, Lau DT, Nguyen MH, Janssen HL, Dieterich DT, Peters MG, Jacobson IM . 2015. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2015 update. Clin Gastroenterol Hepatol 13 : 2071– 2087.e16. doi:10.1016/j.cgh.2015.07.007.[CrossRef].[PubMed] http://dx.doi.org/doi:10.1016/j.cgh.2015.07.007
14. Yan H, Yang Y, Zhang L, Tang G, Wang Y, Xue G, Zhou W, Sun S . 2015. Characterization of the genotype and integration patterns of hepatitis B virus in early- and late-onset hepatocellular carcinoma. Hepatology 61 : 1821– 1831.[CrossRef].[PubMed]
15. Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, Jaoui D, Gaston Mathe Y, Laurent C, Laurent A, Bioulac-Sage P, Calderaro J, Zucman-Rossi J . 2015. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut 64 : 820– 829.[CrossRef].[PubMed]
16. Lieshout-Krikke RW, van Kraaij MG, Danovic F, Zaaijer HL . 2015 Nov 11. Rare transmission of hepatitis B virus by Dutch donors with occult infection. Transfusion doi:10.1111/trf.13401.[CrossRef] http://dx.doi.org/doi:10.1111/trf.13401
17. Kim H, Gong JR, Lee SA, Kim BJ . 2015. Discovery of a novel mutation (X8Del) resulting in an 8-bp deletion in the hepatitis B virus X gene associated with occult infection in Korean vaccinated individuals. PLoS One 10 : e0139551. doi:10.1371/journal.pone.0139551.[CrossRef].[PubMed] http://dx.doi.org/doi:10.1371/journal.pone.0139551
18. Vargas JI, Jensen D, Sarmiento V, Peirano F, Acuña P, Fuster F, Soto S, Ahumada R, Huilcaman M, Bruna M, Jensen W, Fuster F . 2015 Sep 18. Presence of anti-HBc is associated to high rates of HBV resolved infection and low threshold for occult HBV infection in HIV patients with negative HBsAg in Chile. J Med Virol doi:10.1002/jmv.24384.[CrossRef] http://dx.doi.org/doi:10.1002/jmv.24384
19. Ghosh M, Nandi S, Dutta S, Saha MK . 2015. Detection of hepatitis B virus infection: a systematic review. World J Hepatol 7 : 2482– 2491.[CrossRef].[PubMed]
20. Vivekanandan P, Singh OV . 2010. Molecular methods in the diagnosis and management of chronic hepatitis B. Expert Rev Mol Diagn 10 : 921– 935.[CrossRef].[PubMed]
21. Yeh ML, Huang CF, Hsieh MY, Huang JF, Dai CY, Yu ML, Chuang WL . 2014. Comparison of the Abbott RealTime HBV assay with the Roche Cobas AmpliPrep/Cobas TaqMan HBV assay for HBV DNA detection and quantification. J Clin Virol 60 : 206– 214.[CrossRef].[PubMed]
22. Pol J, Le Pendeven C, Beby-Defaux A, Rabut E, Jais JP, Pilloux M, Osada C, Zatla F, Assami H, Grange JD, Kremsdorf D, Nicolas JC, Soussan P . 2008. Prospective comparison of Abbott RealTime HBV DNA and Versant HBV DNA 3.0 assays for hepatitis B DNA quantitation: impact on HBV genotype monitoring. J Virol Methods 154 : 1– 6.[CrossRef].[PubMed]
23. Allice T, Cerutti F, Pittaluga F, Varetto S, Gabella S, Marzano A, Franchello A, Ghisetti V . 2008. Comparison of the Cobas Ampliprep/Cobas TaqMan HBV Test versus the Cobas Amplicor HBV monitor for HBV-DNA detection and quantification during antiviral therapy. New Microbiol 31 : 27– 35.[PubMed]
24. Caviglia GP, Abate ML, Pellicano R, Smedile A . 2015. Chronic hepatitis B therapy: available drugs and treatment guidelines. Minerva Gastroenterol Dietol 61 : 61– 70.[PubMed]
25. Zeng T, Xu H, Liu JY, Lei Y, Zhong S, Zhou Z . 2014. Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: a meta-analysis. J Clin Pharmacol 54 : 959– 967.[CrossRef].[PubMed]
26. Corsa AC, Liu Y, Flaherty JF, Mitchell B, Fung SK, Gane E, Miller MD, Kitrinos KM . 2014. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin Gastroenterol Hepatol 12 : 2106– 2112.e1. doi:10.1016/j.cgh.2014.05.024.[CrossRef].[PubMed] http://dx.doi.org/doi:10.1016/j.cgh.2014.05.024
27. Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bömmel F, Hansen BE, Wedemeyer H, Janssen HL VIRGIL Surveillance Study Group . 2010. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 52 : 493– 500.[CrossRef].[PubMed]
28. Kim HS, Yim HJ, Jang MK, Park JW, Suh SJ, Seo YS, Kim JH, Kim BH, Park SJ, Lee SH, Kim SG, Kim YS, Lee JI, Lee JW, Kim IH, Kim TY, Kim JW, Jeong SH, Jung YK, Park H, Hwang SG Antiviral Resistance Study Group . 2015. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. World J Gastroenterol 21 : 10874– 10882.[CrossRef].[PubMed]
29. Yang J, Chen J, Ye P, Jin L, Wu W, Sheng G, Li LJ . 2014. HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients. J Transl Med 12 : 183. doi:10.1186/1479-5876-12-183.[CrossRef].[PubMed] http://dx.doi.org/doi:10.1186/1479-5876-12-183
30. Kim JH, Moon HW, Ko SY, Choe WH, Kwon SY . 2014. Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B. Clin Mol Hepatol 20 : 274– 282.[CrossRef].[PubMed]
31. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW HBV 99-01 Study Group, Rotterdam Foundation for Liver Research . 2005. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 : 123– 129.[CrossRef].[PubMed]
32. Pas SD, Tran N, de Man RA, Burghoorn-Maas C, Vernet G, Niesters HG . 2008. Comparison of reverse hybridization, microarray, and sequence analysis for genotyping hepatitis B virus. J Clin Microbiol 46 : 1268– 1273.[CrossRef].[PubMed]
33. Niesters HG, Pas S, de Man RA . 2005. Detection of hepatitis B virus genotypes and mutants: current status. J Clin Virol 34( Suppl 1) : S4– S8.[PubMed].[CrossRef]
34. Lupo J, Larrat S, Hilleret MN, Germi R, Boyer V, Nicod S, Barguès G, Leroy V, Seigneurin JM, Zarski JP, Morand P . 2009. Assessment of selective real-time PCR for quantitation of lamivudine and adefovir hepatitis B virus-resistant strains and comparison with direct sequencing and line probe assays. J Virol Methods 156 : 52– 58.[CrossRef].[PubMed]
35. Lee JH, Hong SP, Jang ES, Park SJ, Hwang SG, Kang SK, Jeong SH . 2015. Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B. J Med Virol 87 : 993– 998.[CrossRef].[PubMed]
36. Miyamura T, Saito I, Katayama T, Kikuchi S, Tateda A, Houghton M, Choo QL, Kuo G . 1990. Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis. Proc Natl Acad Sci USA 87 : 983– 987.[PubMed].[CrossRef]
37. Lindenbach BD, Rice CM . 2013. The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol 11 : 688– 700.[CrossRef].[PubMed]
38. De Re V, Gragnani L, Fognani E, Piluso A, Izzo F, Mangia A, Crovatto M, Gava G, Casarin P, Sansonno D, Racanelli V, De Vita S, Pioltelli P, Caggiari L, De Zorzi M, Berretta M, Gini A, Zucchetto A, Buonaguro FM, De Paoli P, Zignego AL . 2014. Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. BioMed Res Int 2014 : 710642. doi:10.1155/2014/710642.[CrossRef].[PubMed] http://dx.doi.org/doi:10.1155/2014/710642
39. Riva A, Laird M, Casrouge A, Ambrozaitis A, Williams R, Naoumov NV, Albert ML, Chokshi S . 2014. Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection. Hepatology 60 : 487– 496.[CrossRef].[PubMed]
40. Laird ME, Mohsen A, Duffy D, Mamdouh R, LeFouler L, Casrouge A, El-Daly M, Rafik M, Abdel-Hamid M, Soulier A, Pawlotsky JM, Hézode C, Rosa I, Renard P, Mohamed MK, Bonnard P, Izopet J, Mallet V, Pol S, Albert ML, Fontanet A . 2014. Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection. J Hepatol 61 : 770– 776.[CrossRef].[PubMed]
41. Karmochkine M, Carrat F, Dos Santos O, Cacoub P, Raguin G . 2006. A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. J Viral Hepat 13 : 775– 782.[CrossRef].[PubMed]
42. Saleh DA, Shebl FM, El-Kamary SS, Magder LS, Allam A, Abdel-Hamid M, Mikhail N, Hashem M, Sharaf S, Stoszek SK, Strickland GT . 2010. Incidence and risk factors for community-acquired hepatitis C infection from birth to 5 years of age in rural Egyptian children. Trans R Soc Trop Med Hyg 104 : 357– 363.[CrossRef].[PubMed]
43. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P . 2013. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 57( Suppl 2) : S39– S45.[CrossRef].[PubMed]
44. Iversen J, Wand H, Topp L, Kaldor J, Maher L . 2013. Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study. Am J Public Health 103 : 1436– 1444.[CrossRef].[PubMed]
45. Panneer N, Lontok E, Branson BM, Teo CG, Dan C, Parker M, Stekler JD, DeMaria A Jr, Miller V . 2014. HIV and hepatitis C virus infection in the United States: whom and how to test. Clin Infect Dis 59 : 875– 882.[CrossRef].[PubMed]
46. Martin NK, Vickerman P, Goldberg D, Hickman M . 2015. HCV treatment as prevention in prison: key issues. Hepatology 61 : 402– 403.[CrossRef].[PubMed]
47. Kamili S, Drobeniuc J, Araujo AC, Hayden TM . 2012. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis 55( Suppl 1) : S43– S48.[CrossRef].[PubMed]
48. Centers for Disease Control and Prevention (CDC) . 2013. Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 62 : 362– 365.[PubMed]
49. Scalioni LP, Cruz HM, de Paula VS, Miguel JC, Marques VA, Villela-Nogueira CA, Milagres FA, Cruz MS, Bastos FI, Andrade TM, Motta-Castro AR, Lewis-Ximenez LL, Lampe E, Villar LM . 2014. Performance of rapid hepatitis C virus antibody assays among high- and low-risk populations. J Clin Virol 60 : 200– 205.[CrossRef].[PubMed]
50. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P . 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59 : 318– 327.[CrossRef].[PubMed]
51. Du H, Qi Y, Hao F, Huang Y, Mao L, Ji S, Huang M, Qin C, Yan R, Zhu X, Zhang C . 2012. Complex patterns of HCV epidemic in Suzhou: evidence for dual infection and HCV recombination in East China. J Clin Virol 54 : 207– 212.[CrossRef].[PubMed]
52. Gededzha MP, Selabe SG, Kyaw T, Rakgole JN, Blackard JT, Mphahlele MJ . 2012. Introduction of new subtypes and variants of hepatitis C virus genotype 4 in South Africa. J Med Virol 84 : 601– 607.[CrossRef].[PubMed]
53. Raghwani J, Thomas XV, Koekkoek SM, Schinkel J, Molenkamp R, van de Laar TJ, Takebe Y, Tanaka Y, Mizokami M, Rambaut A, Pybus OG . 2012. Origin and evolution of the unique hepatitis C virus circulating recombinant form 2k/1b. J Virol 86 : 2212– 2220.[CrossRef].[PubMed]
54. Verbeeck J, Stanley MJ, Shieh J, Celis L, Huyck E, Wollants E, Morimoto J, Farrior A, Sablon E, Jankowski-Hennig M, Schaper C, Johnson P, Van Ranst M, Van Brussel M . 2008. Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol 46 : 1901– 1906.[CrossRef].[PubMed]
55. Nakatani SM, Santos CA, Riediger IN, Krieger MA, Duarte CA, do Carmo Debur M, Carrilho FJ, Ono SK . 2011. Comparative performance evaluation of hepatitis C virus genotyping based on the 5′ untranslated region versus partial sequencing of the NS5B region of Brazilian patients with chronic hepatitis C. Virol J 8 : 459. doi:10.1186/1743-422X-8-459.[CrossRef].[PubMed] http://dx.doi.org/doi:10.1186/1743-422X-8-459
56. Yang R, Cong X, Du S, Fei R, Rao H, Wei L . 2014. Performance comparison of the Versant HCV genotype 2.0 assay (LiPA) and the Abbott Realtime HCV genotype II assay for detecting hepatitis C virus genotype 6. J Clin Microbiol 52 : 3685– 3692.[CrossRef].[PubMed]
57. Mallory MA, Lucic DX, Sears MT, Cloherty GA, Hillyard DR . 2014. Evaluation of the Abbott Realtime HCV genotype II RUO (GT II) assay with reference to 5′UTR, core and NS5B sequencing. J Clin Virol 60 : 22– 26.[CrossRef].[PubMed]
58. Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O . 2013. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. World J Gastroenterol 19 : 8940– 8948.[CrossRef].[PubMed]
59. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM . 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 48 : 1769– 1778.[CrossRef].[PubMed]
60. McCown MF, Rajyaguru S, Kular S, Cammack N, Nájera I . 2009. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 53 : 2129– 2132.[CrossRef].[PubMed]
61. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ . 2013. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368 : 1878– 1887.[CrossRef].[PubMed]
62. Vermehren J, Susser S, Lange CM, Forestier N, Karey U, Hughes E, Ralston R, Tong X, Zeuzem S, Sarrazin C . 2012. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b. J Viral Hepat 19 : 120– 127.[CrossRef].[PubMed]
63. de Carvalho IM, Alves R, de Souza PA, da Silva EF, Mazo D, Carrilho FJ, Queiroz AT, Pessoa MG . 2014. Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches. J Med Virol 86 : 1714– 1721.[CrossRef].[PubMed]
64. Nishiya AS, de Almeida-Neto C, Ferreira SC, Alencar CS, Di-Lorenzo-Oliveira C, Levi JE, Salles NA, Mendrone A Jr, Sabino EC . 2014. HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in São Paulo, Brazil. PLoS One 9 : e86413. doi:10.1371/journal.pone.0086413.[CrossRef].[PubMed] http://dx.doi.org/doi:10.1371/journal.pone.0086413
65. Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, Bruno R, Baldanti F . 2013. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients. Virol J 10 : 355. doi:10.1186/1743-422X-10-355.[CrossRef].[PubMed] http://dx.doi.org/doi:10.1186/1743-422X-10-355
66. Sagnelli E, Sagnelli C, Pisaturo M, Macera M, Coppola N . 2014. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol 20 : 7635– 7643.[CrossRef].[PubMed]
67. Karataylı E, Altunogǧlu YÇ, Karataylı SC, Alagöz SG, Cınar K, Yalçın K, Idilman R, Yurdaydın C, Bozdayı AM . 2014. A one step real time PCR method for the quantification of hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal control. J Clin Virol 60 : 11– 15.[CrossRef]
68. Kodani M, Martin A, Mixson-Hayden T, Drobeniuc J, Gish RR, Kamili S . 2013. One-step real-time PCR assay for detection and quantitation of hepatitis D virus RNA. J Virol Methods 193 : 531– 535.[CrossRef].[PubMed]
69. Brichler S, Le Gal F, Butt A, Chevret S, Gordien E . 2013. Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia. Clin Gastroenterol Hepatol 11 : 734– 740.[CrossRef].[PubMed]
70. Romeo R, Perbellini R . 2015. Hepatitis delta virus: making the point from virus isolation up to 2014. World J Hepatol 7 : 2389– 2395.[CrossRef].[PubMed]
71. Makuwa M, Caron M, Souquière S, Malonga-Mouelet G, Mahé A, Kazanji M . 2008. Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in central Africa. J Clin Microbiol 46 : 754– 756.[CrossRef].[PubMed]
72. Makuwa M, Mintsa-Ndong A, Souquière S, Nkoghé D, Leroy EM, Kazanji M . 2009. Prevalence and molecular diversity of hepatitis B virus and hepatitis delta virus in urban and rural populations in northern Gabon in central Africa. J Clin Microbiol 47 : 2265– 2268.[CrossRef].[PubMed]
73. Foupouapouognigni Y, Noah DN, Sartre MT, Njouom R . 2011. High prevalence and predominance of hepatitis delta virus genotype 1 infection in Cameroon. J Clin Microbiol 49 : 1162– 1164.[CrossRef].[PubMed]
74. Casey JL, Niro GA, Engle RE, Vega A, Gomez H, McCarthy M, Watts DM, Hyams KC, Gerin JL . 1996. Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. J Infect Dis 174 : 920– 926.[PubMed].[CrossRef]
75. Arakawa Y, Moriyama M, Taira M, Hayashi N, Tanaka N, Okubo H, Sugitani M . 2000. Molecular analysis of hepatitis D virus infection in Miyako Island, a small Japanese island. J Viral Hepat 7 : 375– 381.[PubMed].[CrossRef]
76. Ijaz S, Arnold E, Banks M, Bendall RP, Cramp ME, Cunningham R, Dalton HR, Harrison TJ, Hill SF, Macfarlane L, Meigh RE, Shafi S, Sheppard MJ, Smithson J, Wilson MP, Teo CG . 2005. Non-travel-associated hepatitis E in England and Wales: demographic, clinical, and molecular epidemiological characteristics. J Infect Dis 192 : 1166– 1172.[CrossRef].[PubMed]
77. Fu H, Li L, Zhu Y, Wang L, Geng J, Chang Y, Xue C, Du G, Li Y, Zhuang H . 2010. Hepatitis E virus infection among animals and humans in Xinjiang, China: possibility of swine to human transmission of sporadic hepatitis E in an endemic area. Am J Trop Med Hyg 82 : 961– 966.[CrossRef].[PubMed]
78. Norder H, Sundqvist L, Magnusson L, Østergaard Breum S, Löfdahl M, Larsen LE, Hjulsager CK, Magnius L, Böttiger BE, Widén F . 2009. Endemic hepatitis E in two Nordic countries. Euro Surveill 14 : pii=19211. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19211.
79. Meng XJ . 2011. From barnyard to food table: the omnipresence of hepatitis E virus and risk for zoonotic infection and food safety. Virus Res 161 : 23– 30.[CrossRef].[PubMed]
80. Drobeniuc J, Greene-Montfort T, Le NT, Mixson-Hayden TR, Ganova-Raeva L, Dong C, Novak RT, Sharapov UM, Tohme RA, Teshale E, Kamili S, Teo CG . 2013. Laboratory-based surveillance for hepatitis E virus infection, United States, 2005-2012. Emerg Infect Dis 19 : 218– 222, quiz 353.[CrossRef].[PubMed]
81. Matsubayashi K, Kang JH, Sakata H, Takahashi K, Shindo M, Kato M, Sato S, Kato T, Nishimori H, Tsuji K, Maguchi H, Yoshida J, Maekubo H, Mishiro S, Ikeda H . 2008. A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion 48 : 1368– 1375.[CrossRef].[PubMed]
82. Adlhoch C, Kaiser M, Pauli G, Koch J, Meisel H . 2009. Indigenous hepatitis E virus infection of a plasma donor in Germany. Vox Sang 97 : 303– 308.[CrossRef].[PubMed]
83. Colson P, Coze C, Gallian P, Henry M, De Micco P, Tamalet C . 2007. Transfusion-associated hepatitis E, France. Emerg Infect Dis 13 : 648– 649.[CrossRef].[PubMed]
84. Slot E, Hogema BM, Riezebos-Brilman A, Kok TM, Molier M, Zaaijer HL . 2013. Silent hepatitis E virus infection in Dutch blood donors, 2011 to 2012. Euro Surveill 18 : 20550. http://dx.doi.org/10.2807/1560-7917.ES2013.18.31.20550.[PubMed].[CrossRef]
85. Hewitt PE, Ijaz S, Brailsford SR, Brett R, Dicks S, Haywood B, Kennedy IT, Kitchen A, Patel P, Poh J, Russell K, Tettmar KI, Tossell J, Ushiro-Lumb I, Tedder RS . 2014. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet 384 : 1766– 1773.[CrossRef].[PubMed]
86. Cleland A, Smith L, Crossan C, Blatchford O, Dalton HR, Scobie L, Petrik J . 2013. Hepatitis E virus in Scottish blood donors. Vox Sang 105 : 283– 289.[CrossRef].[PubMed]
87. Huang S, Zhang X, Jiang H, Yan Q, Ai X, Wang Y, Cai J, Jiang L, Wu T, Wang Z, Guan L, Shih JW, Ng MH, Zhu F, Zhang J, Xia N . 2010. Profile of acute infectious markers in sporadic hepatitis E. PLoS One 5 : e13560. doi:10.1371/journal.pone.0013560.[CrossRef].[PubMed] http://dx.doi.org/doi:10.1371/journal.pone.0013560
88. Bendall R, Ellis V, Ijaz S, Ali R, Dalton H . 2010. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol 82 : 799– 805.[CrossRef].[PubMed]
89. Pas SD, Streefkerk RH, Pronk M, de Man RA, Beersma MF, Osterhaus AD, van der Eijk AA . 2013. Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients. J Clin Virol 58 : 629– 634.[CrossRef].[PubMed]
90. Ferguson M, Walker D, Mast E, Fields H . 2002. Report of a collaborative study to assess the suitability of a reference reagent for antibodies to hepatitis E virus. Biologicals 30 : 43– 48.[CrossRef].[PubMed]
91. Pas SD, Streefkerk RH, Pronk M, de Man RA, Beersma MF, Osterhaus AD, van der Eijk AA . 2013. Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients. J Clin Virol 58 : 629– 634.[CrossRef].[PubMed]
92. Baylis SA, Blümel J, Mizusawa S, Matsubayashi K, Sakata H, Okada Y, Nübling CM, Hanschmann KM HEV Collaborative Study Group. 2013. World Health Organization International Standard to harmonize assays for detection of hepatitis E virus RNA. Emerg Infect Dis 19 : 729– 735.[CrossRef].[PubMed]
93. Abravanel F, Chapuy-Regaud S, Lhomme S, Dubois M, Peron JM, Alric L, Rostaing L, Kamar N, Izopet J . 2013. Performance of two commercial assays for detecting hepatitis E virus RNA in acute or chronic infections. J Clin Microbiol 51 : 1913– 1916.[CrossRef].[PubMed]
94. Mokhtari C, Marchadier E, Haïm-Boukobza S, Jeblaoui A, Tessé S, Savary J, Roque-Afonso AM . 2013. Comparison of real-time RT-PCR assays for hepatitis E virus RNA detection. J Clin Virol 58 : 36– 40.[CrossRef].[PubMed]
95. Kamar N, Rostaing L, Legrand-Abravanel F, Izopet J . 2013. How should hepatitis E virus infection be defined in organ-transplant recipients? Am J Transplant 13 : 1935– 1936.[CrossRef].[PubMed]
96. Kamar N, Izopet J, Dalton HR . 2013. Chronic hepatitis E virus infection and treatment. J Clin Exp Hepatol 3 : 134– 140.[CrossRef].[PubMed]
97. Tang X, Yang C, Gu Y, Song C, Zhang X, Wang Y, Zhang J, Hew CL, Li S, Xia N, Sivaraman J . 2011. Structural basis for the neutralization and genotype specificity of hepatitis E virus. Proc Natl Acad Sci USA 108 : 10266– 10271.[CrossRef].[PubMed]
98. Zhang J, Liu CB, Li RC, Li YM, Zheng YJ, Li YP, Luo D, Pan BB, Nong Y, Ge SX, Xiong JH, Shih JW, Ng MH, Xia NS . 2009. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine 27 : 1869– 1874.[CrossRef].[PubMed]
99. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, Wang YJ, Ai X, Hu YM, Tang Q, Yao X, Yan Q, Xian YL, Wu T, Li YM, Miao J, Ng MH, Shih JW, Xia NS . 2010. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, 3 trial. Lancet 376 : 895– 902.[CrossRef].[PubMed]
100. Kamar N, Garrouste C, Haagsma EB, Garrigue V, Pischke S, Chauvet C, Dumortier J, Cannesson A, Cassuto-Viguier E, Thervet E, Conti F, Lebray P, Dalton HR, Santella R, Kanaan N, Essig M, Mousson C, Radenne S, Roque-Afonso AM, Izopet J, Rostaing L . 2011. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 140 : 1481– 1489.[CrossRef].[PubMed]
101. Kamar N, Dalton HR, Abravanel F, Izopet J . 2014. Hepatitis E virus infection. Clin Microbiol Rev 27 : 116– 138.[CrossRef].[PubMed]
102. Takahashi M, Tanaka T, Takahashi H, Hoshino Y, Nagashima S, Jirintai , Mizuo H, Yazaki Y, Takagi T, Azuma M, Kusano E, Isoda N, Sugano K, Okamoto H . 2010. Hepatitis E virus (HEV) strains in serum samples can replicate efficiently in cultured cells despite the coexistence of HEV antibodies: characterization of HEV virions in blood circulation. J Clin Microbiol 48 : 1112– 1125.[CrossRef].[PubMed]
103. Shukla P, Nguyen HT, Faulk K, Mather K, Torian U, Engle RE, Emerson SU . 2012. Adaptation of a genotype 3 hepatitis E virus to efficient growth in cell culture depends on an inserted human gene segment acquired by recombination. J Virol 86 : 5697– 5707.[CrossRef].[PubMed]

Tables

Viral Hepatitis
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555818722.ch65-1,webId=/content/author/10.1128/9781555818722.ch65-1,properties={foaf_givenname=Hubert G. M., foaf_name=Hubert G. M. Niesters, foaf_surname=Niesters, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555818722.ch65-aff1]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555818722.ch65-2,webId=/content/author/10.1128/9781555818722.ch65-2,properties={foaf_givenname=Annelies, foaf_name=Annelies Riezebos-Brilman, foaf_surname=Riezebos-Brilman, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555818722.ch65-aff2]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555818722.ch65-3,webId=/content/author/10.1128/9781555818722.ch65-3,properties={foaf_givenname=Coretta C., foaf_name=Coretta C. Van Leer-Buter, foaf_surname=Van Leer-Buter, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555818722.ch65-aff3]]}]]
Citation: Niesters H, Riezebos-Brilman A, Van Leer-Buter C. 2016. Viral Hepatitis, p 620-638. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch65
/content/10.1128/9781555818722.ch65.ch65tab1
TABLE 1

Characteristics of the five primary hepatitis viruses

Generic image for table
TABLE 1

Characteristics of the five primary hepatitis viruses

Citation: Niesters H, Riezebos-Brilman A, Van Leer-Buter C. 2016. Viral Hepatitis, p 620-638. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch65
/content/10.1128/9781555818722.ch65.ch65tab2
TABLE 2

Clinical forms of hepatitis

Generic image for table
TABLE 2

Clinical forms of hepatitis

Citation: Niesters H, Riezebos-Brilman A, Van Leer-Buter C. 2016. Viral Hepatitis, p 620-638. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch65
/content/10.1128/9781555818722.ch65.ch65tab3
TABLE 3

Algorithm and interpretation of serological and molecular tests for the detection of HAV

Generic image for table
TABLE 3

Algorithm and interpretation of serological and molecular tests for the detection of HAV

Citation: Niesters H, Riezebos-Brilman A, Van Leer-Buter C. 2016. Viral Hepatitis, p 620-638. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch65
/content/10.1128/9781555818722.ch65.ch65tab4
TABLE 4

Algorithm and interpretation of serological and molecular tests for the detection of HBV

Generic image for table
TABLE 4

Algorithm and interpretation of serological and molecular tests for the detection of HBV

Citation: Niesters H, Riezebos-Brilman A, Van Leer-Buter C. 2016. Viral Hepatitis, p 620-638. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch65
/content/10.1128/9781555818722.ch65.ch65tab5
TABLE 5

Algorithm and interpretation of serological and molecular tests for the detection of HCV

Generic image for table
TABLE 5

Algorithm and interpretation of serological and molecular tests for the detection of HCV

Citation: Niesters H, Riezebos-Brilman A, Van Leer-Buter C. 2016. Viral Hepatitis, p 620-638. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch65
/content/10.1128/9781555818722.ch65.ch65tab6
TABLE 6

Algorithm and interpretation of serological and molecular tests for the detection of HDV

Generic image for table
TABLE 6

Algorithm and interpretation of serological and molecular tests for the detection of HDV

Citation: Niesters H, Riezebos-Brilman A, Van Leer-Buter C. 2016. Viral Hepatitis, p 620-638. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch65
/content/10.1128/9781555818722.ch65.ch65tab7
TABLE 7

Algorithm and interpretation of serological and molecular tests for the detection of HEV

Generic image for table
TABLE 7

Algorithm and interpretation of serological and molecular tests for the detection of HEV

Citation: Niesters H, Riezebos-Brilman A, Van Leer-Buter C. 2016. Viral Hepatitis, p 620-638. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch65

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error